The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Impact of leukemic molecular profile on the efficacy of inotuzumab ozogamicin in R/R ALL
|
Results from the phase III INO-VATE (NCT01564784) trial evaluating the efficacy of inotuzumab ozogamicin (InO) for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL) were published in Blood Advances by Zhao et al.1 Responses to InO were recorded in 91 patients by leukemic subtype, genomic alterations, and risk status.
|
| Key learnings |
|
The median overall survival was 7.7 months with InO compared with 6.2 months with standard of care (SoC) chemotherapy (hazard ratio, 0.75; p = 0.0105). |
|
Patients with high-risk molecular profiles experienced improved complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates with InO compared with SoC chemotherapy (74.7% vs 33.3%; p < 0.001).
|
|
The CR rate in patients with TP53 alterations was also higher with InO compared with SoC chemotherapy (100% vs 12.5%; p = 0.0047). |
|
The findings from the study suggest that InO may be a viable option for patients with R/R ALL, particularly those with high-risk molecular profiles, offering personalized treatment strategies. Further exploration of InO efficacy is needed in patients with BCR::ABL1-like subtype and TP53 alterations.
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
